Cell Therapeutics (CTIC) is up 22 cents to $1.12 per share and calls are active in early trading after the FDA completed a review of a new overseas plant that manufactures pixantrone and found the site in compliance. Shares are up and early action includes a sweep of 4000 Sep 5 calls at a nickel. Looks like an opening lottery ticket buyer.